Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major Stargardt disease markets are expected to exhibit a CAGR of 22.82% during 2024-2034.

The Stargardt disease market has been comprehensively analyzed in IMARC's new report titled "Stargardt Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Stargardt disease refers to an inherited single-gene disorder that affects the retina, which is the part of the eye that detects light and sends visual information to the brain. The ailment is characterized by macular degeneration that begins in childhood, adolescence, or adulthood, causing progressive loss of vision. The primary symptom of the disease is a decrease in visual acuity, which cannot be corrected with glasses. This manifests as a diminished ability to see fine details while viewing or reading distant objects. Various other common indications associated with Stargardt disease include wavy vision, blurriness, blind spots, loss of depth perception, impaired color vision, sensitivity to glare, difficulty adapting to dim lighting, etc. The diagnosis of the condition is mainly made through clinical features, medical history, and an eye examination via slit lamp. The healthcare provider may also perform genetic testing to ensure the presence of genome abnormalities within the body. Numerous diagnostic tools, such as spectral-domain optical coherence tomography, microperimetry, electroretinography, etc., are utilized in patients to confirm a diagnosis and rule out other possible causes.

The increasing prevalence of genetic disorders caused by mutations in one of several genes involved in the processing of vitamin A in the retina is primarily driving the Stargardt disease market. In addition to this, the widespread adoption of intravitreal vasodilators, including dobesilate, that inhibit overexpression of fibroblast growth factor and improve visual acuity in patients is also bolstering the market growth. Furthermore, the inflating application of fluorescein angiography for diagnosing various ocular pathologies by assessing the anatomy and physiology of retinal and choroidal circulation is acting as another significant growth-inducing factor. Apart from this, the escalating demand for vision rehabilitation therapy to treat the ailment, since it can maximize visual functioning and improve the quality of life for patients, is further creating a positive outlook for the market. Moreover, the emerging popularity of gene replacement therapy, which works by replacing the incorrect gene variant with the correct version, thereby enhancing the body's ability to fight the condition, is expected to drive the Stargardt disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Stargardt disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Stargardt disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Stargardt disease market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Stargardt disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Stargardt disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Stargardt disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the Stargardt disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Stargardt disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Stargardt disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Stargardt disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Stargardt disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Stargardt disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Stargardt disease across the seven major markets?
What is the size of the Stargardt disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Stargardt disease?
What will be the growth rate of patients across the seven major markets?

Stargardt Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Stargardt disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Stargardt disease market?
What are the key regulatory events related to the Stargardt disease market?
What is the structure of clinical trial landscape by status related to the Stargardt disease market?
What is the structure of clinical trial landscape by phase related to the Stargardt disease market?
What is the structure of clinical trial landscape by route of administration related to the Stargardt disease market?